We establish collaborative relationships with biotechnology companies and academic research organizations to identify lead compounds for development. Current partners include:


Through a strategic collaboration and licensing agreement, Tanabe is leveraging MedImmune’s pyrrolobenzodiazepine (PBD)-based warhead and linker technology to generate monospecific and bispecific antibody-drug conjugates for investigation in various cancers.


Through our collaboration with Covagen, we are using its proprietary Fynomer®-antibody platform to generate bispecific proteins (known as FynomAbs) against target pairs selected by the Tanabe team. Fynomers are small proteins that can be engineered to bind to various antigens of interest. FynomAbs will be used as therapeutic agents in autoimmune diseases and cancer.